Pharma Manufacturing Waste: The CPCB Audit Failures Driving Plant Shutdowns

Updated: September 23, 2026 · 17 min read

Between April 2025 and August 2026, the Central Pollution Control Board (CPCB) issued show-cause notices to more than 60 pharmaceutical manufacturing units across Telangana, Gujarat, and Himachal Pradesh — the three states that together account for roughly 55% of India’s bulk drug output. The proximate cause in the majority of cases was not a catastrophic spill or a dramatic effluent release. It was paperwork: missing manifest acknowledgements, lapsed hazardous-waste authorisations, and ETP capacity logs that did not match actual production volumes. Pharma manufacturing waste compliance, long treated as a back-office task, is now a front-door risk to plant continuity.

The Audit Wave That Is Closing Pharma Plants in 2026

The enforcement surge did not materialise from nowhere. The Ministry of Environment, Forest and Climate Change (MoEFCC) directed SPCBs in late 2024 to intensify inspections of Red-category industries — a category that includes virtually every active pharmaceutical ingredient (API) manufacturing site — with a target of completing at least two unannounced inspections per unit per financial year. That directive, communicated through the CPCB’s consolidated guidelines on hazardous waste enforcement, shifted the audit rhythm from predictable annual visits to rolling, unscheduled checks.

The timing is not coincidental. India’s pharmaceutical sector processed an estimated 8.5 lakh tonnes of chemical waste in FY 2025-26, of which hazardous fractions — solvents, mother liquors, spent catalysts, off-spec APIs — constituted approximately 2.3 lakh tonnes. Against that volume, authorised treatment, storage, and disposal facility (TSDF) capacity across the country remains stubbornly under-built. The CPCB’s own data from its last published hazardous waste inventory showed that 11 states had TSDF capacity utilisation above 85%, leaving no buffer for compliance lapses.

For plant heads in Hyderabad’s Genome Valley cluster or Gujarat’s Ankleshwar industrial belt, the practical consequence is stark: a single unannounced inspection revealing inadequate manifest records can produce a closure notice within 72 hours, with reinstatement conditional on producing documentary proof of remediation — a process that routinely takes four to six weeks even when the underlying issue is minor.

The Regulatory Framework Every Plant Head Must Know

Three instruments dominate pharma manufacturing waste compliance in India, and auditors cross-reference all three simultaneously.

Hazardous and Other Wastes (Management & Transboundary Movement) Rules, 2016

These rules — notified under the Environment Protection Act, 1986 — are the primary compliance instrument. They classify pharmaceutical process waste under Schedule I (wastes having constituents listed therein) and require every occupier generating more than 10 kg/day of any listed hazardous waste to obtain prior authorisation from the relevant SPCB. The CPCB’s hazardous waste portal hosts the authorisation application workflow, but the issuing authority is the State Board. Authorisations must be renewed before expiry — typically every five years — and the renewal application must be filed at least 120 days before the existing authorisation lapses. Many plants that received authorisations in 2020 and 2021 missed the FY 2025-26 renewal window; their operations continued, but the legal basis for generating, storing, and transporting hazardous waste had already evaporated.

Environment Protection Act, 1986 — Section 15 Penalty Provisions

Section 15 of the Environment Protection Act, 1986 provides for imprisonment of up to five years and a fine of up to ₹1 lakh for the first offence, with a further penalty of ₹5,000 per day for every day the violation continues beyond the first conviction. Critically, the Act imposes personal liability on the person in charge of the company at the time of the offence — meaning the plant head and, in some SPCBs’ practice, the EHS Manager can be named as accused individuals, not merely the corporate entity.

Biomedical Waste Management Rules, 2016

Pharma plants with on-site dispensaries, clinical trial units, or quality-control laboratories that handle biological samples also fall under the Biomedical Waste Management Rules, 2016. These rules require separate colour-coded segregation, dedicated storage not exceeding 48 hours, and disposal only through an authorised common biomedical waste treatment facility (CBWTF). CPCB auditors routinely check whether pharma plants have conflated BMW waste streams with general chemical waste — a mixing that voids the authorisation for both streams and triggers independent penalty proceedings.

Seven Recurring Audit Failures — and the Fines They Attract

The table below synthesises the most common non-conformities reported in CPCB inspection reports and SPCB closure notices for pharma units during FY 2025-26. It is not exhaustive, but it covers the deficiencies that appear in more than 70% of enforcement actions reviewed.

Audit Finding	Applicable Rule	Typical Penalty / Consequence
Expired or missing SPCB hazardous-waste authorisation	HW Rules, 2016 — Rule 6	Immediate closure notice; ₹1 lakh/day under EP Act Section 15
Manifest records incomplete or not retained for 5 years	HW Rules, 2016 — Rule 19	Show-cause notice; licence suspension pending audit
ETP design capacity below actual wastewater generation	Consent to Operate conditions under Water (Prevention & Control of Pollution) Act, 1974	Consent revocation; production halt order
On-site storage of hazardous waste beyond 90 days without SPCB approval	HW Rules, 2016 — Rule 7(3)	Penalty notice; forced evacuation to TSDF at plant’s cost
Expired pharmaceutical stock disposed of in municipal landfill	HW Rules, 2016 — Schedule II	Criminal complaint under EP Act; DGFT export-licence flag
Solvent recovery unit not covered in Consent to Operate	Air (Prevention & Control of Pollution) Act, 1981	Show-cause notice; ₹25,000-₹1 lakh spot fine
Biomedical and chemical waste streams mixed in storage area	BMW Rules, 2016 — Schedule I & II	Dual non-compliance; separate proceedings under both rules

ETP and Incineration Adequacy: Where the Biggest Gaps Sit

Effluent treatment plant (ETP) adequacy is the single largest technical non-conformity in CPCB inspection reports for pharma units. The core problem is simple: API manufacturing is dynamic. A plant wins a new synthesis contract, scales up production by 30-40%, and the ETP — designed to treat a lower baseline wastewater volume — is immediately under-capacity. The Consent to Operate issued by the SPCB specifies maximum permissible effluent generation per day; exceeding that figure without obtaining a Consent amendment is a standalone violation even if the treated effluent meets discharge standards.

Incineration is the other half of the treatment equation, particularly for chlorinated solvents, spent mother liquors, and cytotoxic waste streams. Rule 12 of the Hazardous and Other Wastes Rules, 2016 requires that incineration facilities meet the emission standards prescribed by the CPCB, and that pharma units verify those standards before signing a disposal contract. In practice, many plants hold agreements with common incinerators whose operational certificates have lapsed or whose stack emission data has not been submitted to the SPCB for the current financial year. When an auditor checks the incinerator’s current compliance status on the SPCB portal and finds a gap, the pharma plant’s disposal records are immediately classified as non-compliant — regardless of how carefully the plant’s own paperwork was maintained.

The Telangana and Gujarat Patterns

Telangana’s TSPCB has been particularly active in the Genome Valley and IDA Jeedimetla clusters. Between October 2025 and March 2026, it issued production-halt orders to 14 API manufacturers for ETP overflow events during the monsoon season — events that the plants attributed to abnormal rainfall but which the TSPCB determined were the foreseeable consequence of inadequate ETP buffer capacity. In Gujarat’s Ankleshwar and Panoli industrial estates, the GPCB’s joint inspections with the CPCB’s zonal office in Ahmedabad flagged 19 units for storing hazardous pharmaceutical waste beyond the 90-day on-site limit prescribed under Rule 7(3) of the Hazardous Waste Rules, 2016 — a finding directly attributable to the chronic under-supply of TSDF capacity in the region.

Manifest Discipline: The Paperwork Gap That Shuts Plants Down

Pharma manufacturing waste compliance auditors treat the hazardous waste manifest as the single most important document in an inspection. Rule 19 of the Hazardous and Other Wastes Rules, 2016 requires the occupier (the pharma plant), the transporter, and the authorised disposer each to hold a copy of the manifest, with the disposer’s acknowledgement copy returned to the occupier within 30 days of delivery. The occupier must then retain all manifests for a minimum of five years and make them available to the CPCB or SPCB on demand.

The failure modes are well-documented. Transporters routinely fail to return the acknowledgement copy within 30 days; plants accept this informally and log the waste as “disposed” in their internal records. When an auditor asks to see manifest acknowledgements for the preceding 12 months, gaps of 20-40% are common at mid-sized formulation plants. Each missing acknowledgement is a distinct violation. At a plant generating 50 manifest movements per year, a 30% gap translates to 15 separate non-conformities — each attracting independent penalty proceedings under the EP Act.

The digital manifest system introduced by CPCB — accessible via the Paryavaran portal — was intended to close this gap by making acknowledgement electronic and time-stamped. However, uptake remains inconsistent, particularly among smaller transporters operating in Himachal Pradesh and Uttarakhand’s pharma clusters. Plants in those clusters that rely on paper manifests and manual acknowledgement chasing face a structurally higher audit risk than those that have integrated their waste management with transporters who are active on the digital system.

Expired Drug Stock and Off-Spec API: The Disposal Protocol Auditors Check First

Expired pharmaceutical products and off-specification API batches sit at the intersection of drug regulation and environmental law. The drugs themselves fall under the Drugs and Cosmetics Act, 1940, which requires that expired drugs not be sold or redistributed. The waste they constitute, however, falls squarely under Schedule II of the Hazardous and Other Wastes Rules, 2016, which lists pharmaceutical waste as a category requiring incineration at an authorised facility — not landfilling, not co-processing without specific approval, and certainly not sale to unlicensed waste dealers.

The CPCB’s inspections in FY 2025-26 found that a significant number of mid-sized formulation plants in Maharashtra and Rajasthan had been routing expired stock to municipal solid waste contractors — partly because authorised incineration rates (typically ₹18-₹35 per kg depending on waste category and facility) make proper disposal feel expensive against the backdrop of zero recovery value. The short-term cost saving is illusory: a single detection of pharmaceutical waste in a municipal landfill produces both an environmental complaint under the EP Act and a drug-quality complaint to the State Drug Authority, creating concurrent regulatory exposure that no plant’s legal team wants to manage simultaneously.

The correct protocol is: quantify the expired stock batch by batch, prepare a destruction advice with batch number, quantity in kg, reason for disposal, and intended disposal method; route to an authorised incineration facility under a proper manifest; obtain a certificate of destruction from the facility; and retain both the manifest and the certificate for five years. Our industrial waste management service connects plants with CPCB-authorised incineration partners who issue destruction certificates meeting SPCB audit standards.

The Export-Licence Linkage Most Compliance Teams Miss

India’s pharmaceutical export sector generated approximately $27.9 billion (roughly ₹2.3 lakh crore) in revenue in FY 2025-26, making it one of the country’s largest hard-currency earners. What most plant-level EHS teams do not appreciate is that hazardous waste compliance status is now factored into export licensing and Good Manufacturing Practice (GMP) certifications that underpin market access.

The linkage works through two channels. First, DGFT’s export licensing conditions for certain scheduled chemicals and API intermediates require the applicant to certify compliance with all environmental clearances and SPCB consents. A plant operating with a lapsed hazardous-waste authorisation technically makes a false declaration when it certifies full compliance — a risk that has escalated since the DGFT began cross-referencing CPCB’s non-compliant industry database before processing certain chemical export applications.

Second, international buyers — particularly in the EU and the United States — are conducting increasingly granular environmental due diligence on Indian API suppliers. US FDA inspections routinely examine environmental management systems, and a pattern of SPCB enforcement actions against a plant can influence an FDA investigator’s risk assessment. EU pharmaceutical buyers under the EU Green Deal’s supply chain sustainability framework are beginning to require supplier declarations on hazardous waste disposal — declarations that a plant with outstanding CPCB show-cause notices cannot honestly make. The reputational and commercial exposure from a compliance gap thus extends well beyond the domestic penalty regime.

Q3 FY 2026-27 Compliance Checklist for Pharma EHS Teams

Given the enforcement intensity of the current cycle, the following actions are time-sensitive for any pharma plant that has not conducted an internal waste compliance audit since April 2026.

1. Verify SPCB hazardous-waste authorisation validity. Check the expiry date on the authorisation certificate. If it expires before 31 March 2027, file the renewal application immediately — SPCB processing timelines frequently run 90-120 days, and an expired authorisation during the interim period is not excused by a pending renewal application.
2. Audit ETP capacity against current production volumes. Pull the past six months’ production records and calculate actual wastewater generation per day. Compare against the design capacity stated in your Consent to Operate. If actual generation exceeds Consent limits by more than 10%, initiate a Consent amendment application without delay.
3. Reconcile manifest records for FY 2025-26. For every hazardous waste consignment dispatched in FY 2025-26, confirm that the disposer’s acknowledgement copy has been received and filed. Chase outstanding acknowledgements in writing; document all follow-up. Missing acknowledgements older than 60 days should be reported to the transporter’s SPCB for intervention.
4. Verify the compliance status of your incineration/TSDF partner. Log into your state SPCB’s public portal and confirm that your disposal contractor’s authorisation is current and that their latest stack emission or ETP discharge data has been filed. Do not rely on the contractor’s verbal assurances — auditors check the portal directly.
5. Conduct a physical inventory of expired and off-spec stock. Identify all batches beyond shelf-life or rejected at QC. Quantify by weight. Prepare destruction advice documentation for each batch and arrange incineration within 90 days of identification to remain within on-site storage limits under Rule 7(3).
6. Check digital manifest registration on the Paryavaran portal. If your plant or your transporter is not yet on the CPCB’s digital manifest system, complete registration now. CPCB’s regional offices have indicated that digital manifest compliance will be a standalone inspection criterion from FY 2027-28 onwards.
7. Review export-licence declarations for environmental compliance certifications. Work with your regulatory affairs team to confirm that all DGFT export applications filed in the current financial year accurately reflect your SPCB consent and hazardous-waste authorisation status. If any declaration was made against a subsequently lapsed authorisation, take legal advice on remediation.
8. Train production supervisors on waste segregation at source. Manifest discipline begins at the point of waste generation. Supervisors who mix solvent waste with aqueous effluent, or who log estimated weights rather than weighed quantities, create the discrepancies that auditors find most damning — because they suggest systemic, not accidental, non-compliance.

Related Articles

• How Much Does EPR Actually Cost an Indian SME? A Real-Numbers Breakdown
• BIS Standards for Recycled Materials: What’s Notified, What’s Coming, What It Means for Buyers
• Election-Year Policy Risk: How a Change in Government Could Reshape India’s Recycling Rules

Frequently Asked Questions

What is the minimum threshold for pharma plants to require SPCB hazardous-waste authorisation?

Under Rule 6 of the Hazardous and Other Wastes (Management & Transboundary Movement) Rules, 2016, any occupier generating 10 kg or more per day of a waste listed in Schedule I, II, or III must obtain prior authorisation from the relevant SPCB before generating, storing, or disposing of that waste. For API manufacturing, virtually every production line will cross this threshold given the quantities of spent solvents and process residues involved. Authorisation is plant-specific — a company with multiple sites must hold separate authorisations for each.

How long must hazardous waste manifests be retained at a pharma plant?

Rule 19(5) of the Hazardous and Other Wastes Rules, 2016 requires the occupier to retain manifest records for a minimum of five years. Auditors routinely request three to five years of manifest history during inspections. The retention obligation applies to all copies — both the occupier’s own copy and the disposer’s acknowledgement copy. Failure to produce complete records for any 12-month period within that window is treated as evidence of disposal through an unauthorised route, which is among the most serious findings an auditor can record.

Can expired pharmaceutical stock be sent to a municipal landfill if it is in sealed packaging?

No. Schedule II of the Hazardous and Other Wastes (Management & Transboundary Movement) Rules, 2016 classifies pharmaceutical waste — including expired medicines and off-specification APIs — as hazardous, regardless of packaging. The prescribed disposal method is incineration at a CPCB-authorised facility. Disposal at a municipal landfill is a cognisable offence under the Environment Protection Act, 1986, attracting penalties of up to ₹1 lakh plus continuing fines of ₹5,000 per day. It also triggers a drug-authority complaint under the Drugs and Cosmetics Act, 1940, creating parallel regulatory exposure.

What documentation should a pharma plant obtain from its incineration or TSDF partner?

At minimum, a pharma plant should obtain: (a) a copy of the TSDF or incinerator’s current SPCB authorisation, (b) a signed manifest for each consignment despatched, (c) the disposer’s acknowledgement copy of the manifest within 30 days of delivery as required under Rule 19, and (d) a certificate of destruction or treatment that specifies the batch numbers, quantities, and method of disposal. This documentation set satisfies both SPCB auditors and the export-related due-diligence requirements of international pharmaceutical buyers. Retain all documents for five years at minimum.

How does hazardous waste non-compliance affect a pharma plant’s DGFT export licence?

DGFT export licence applications for scheduled chemicals and certain API intermediates require the applicant to certify that all environmental clearances and SPCB consents are valid and current. A plant with a lapsed hazardous-waste authorisation or an outstanding CPCB closure notice cannot make that certification truthfully. Beyond the legal exposure, DGFT has been cross-referencing CPCB’s publicly accessible list of non-compliant industries since FY 2025-26 for certain chemical export categories. A compliance gap discovered during DGFT review can delay export licences by several months — a commercially catastrophic outcome for plants supplying on fixed delivery schedules to international buyers.

Work With The National Recycling Corporation

The National Recycling Corporation is a Mumbai-headquartered, pan-India industrial waste management and scrap trading company with active operations across Maharashtra, Gujarat, Telangana, Karnataka, Tamil Nadu, and Delhi-NCR. We work with pharmaceutical manufacturers, API producers, formulation plants, and contract research organisations to build waste disposal chains that pass CPCB and SPCB audits — not just on paper, but operationally.

Our value to pharma EHS teams rests on three capabilities. First, we maintain relationships with CPCB-authorised TSDF and incineration facilities across the country, and we verify their compliance status before recommending them to clients — because your audit exposure is directly linked to your disposal partner’s compliance record. Second, every consignment we handle is accompanied by a full manifest trail, GST-compliant invoicing, and a certificate of destruction or recycling that meets SPCB documentation requirements. Third, for recoverable materials — scrap metals from pharmaceutical equipment, packaging waste, clean solvent streams eligible for recovery — we apply fair-market pricing indexed to current LME benchmarks for metals, ensuring your plant realises value from the waste it legitimately can.

For pharma manufacturing waste compliance that withstands inspection scrutiny, we are equipped to help. Contact us to discuss your plant’s requirements. You may also find our full-service industrial waste management and EPR compliance services relevant to your broader regulatory obligations.

• Pan-India pickup and logistics for hazardous pharmaceutical waste
• CPCB-authorised disposal and incineration partners — compliance-verified
• Full manifest chain management and five-year document retention support
• Certificates of destruction accepted by SPCB auditors and international buyers
• GST-compliant invoicing for all waste disposal transactions
• Fair-market recovery pricing for scrap metals and recoverable materials from pharma operations
• BRSR-grade waste disposal documentation for listed pharma companies with ESG reporting obligations

Sources and References

• CPCB — Hazardous Waste Management: Rules, Authorisation and Manifest System
• Ministry of Environment, Forest and Climate Change — Environment Protection Act, 1986 and subordinate rules
• Central Pollution Control Board — Inspection and Enforcement Reports, FY 2025-26
• MoEFCC — Hazardous Substance Management Division: Hazardous and Other Wastes (Management & Transboundary Movement) Rules, 2016
• NITI Aayog — Circular Economy and Industrial Waste Policy Framework
• CPCB — Biomedical Waste Management Rules, 2016: Compliance Guidelines for Healthcare and Pharma Facilities
• Press reports — Business Standard and Economic Times coverage of TSPCB and GPCB enforcement actions, October 2025–March 2026 (referenced generally; specific headlines not reproduced)
• The National Recycling Corporation — Industrial Waste Management Services